COMPASS Pathways Archives

Psychedelics News

COMPASS Pathways

Industry

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

Events, Industry

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

Breaking News

19 Feb 2026

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

By Madison Roberts

Breaking News

16 Aug 2023

COMPASS Pathways Announces Capital Raise of Up to $285 Million

COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Science

17 Jul 2023

Positive Data From COMPASS Pathways’ Phase 2 Trial Combining Psilocybin & SSRIs

Results of COMPASS Pathways’ study suggests that SSRIs do not interfere with the potential therapeutic effect of COMP360...

By Microdose NewsDesk

Finance

6 Jul 2023

COMPASS Pathways Secures $50 Million in Capital

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital...

By Microdose NewsDesk

Finance

6 Jun 2023

Compass Pathways’ Stock Soars as COMP360 Receives Patent Victory

Compass Pathways’ COMP360 has just received additional support for its IP strategy, with the US Patent and Trademark Office upholding patent protections on the compound....

By Microdose NewsDesk

Industry

1 Jun 2023

Compass Pathways’ COMP360 Produces 50% Long-Term Depression Remission in Cancer Patients

Late last week we received news that Compass Pathways' psilocybin compound COMP360 produced extremely positive results in alleviating depression results in cancer patients....

By Jason Najum

Finance

12 May 2023

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

COMPASS Pathways reported its financial results for the first quarter 2023 and gave an update on recent progress across its business....

By Microdose NewsDesk

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result